Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
As part of the License Agreement, Crescita will receive an upfront payment in cash of US$125,000 and will be eligible for regulatory and sales milestones of up to US$1.0 The Peel technology consists of a drug-containing cream which, once applied to a patient’s skin, dries to form a pliable layer that releases drug into the skin.
40 
Let's personalize your content